Greenwich LifeSciences Updates CEO Interviews, Corporate Events Schedule.

Greenwich LifeSciences, a clinical-stage biopharmaceutical company, has provided an update on CEO interviews and corporate events. The company's CEO has been featured in interviews on Bloomberg TV and Charles Schwab Network, and has also participated in a live fireside chat with a research analyst at Noble Virtual Conference. The company's recent events include the Jefferies London Healthcare Conference, San Antonio Breast Cancer Symposium, and a poster presentation.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI), a clinical-stage biopharmaceutical company, has recently provided an update on CEO interviews and corporate events. The company's CEO has been featured in interviews on Bloomberg TV and Charles Schwab Network, and has also participated in a live fireside chat with a research analyst at Noble Virtual Conference. Additionally, the company has maintained an active presence at major industry events, including the Jefferies London Healthcare Conference, San Antonio Breast Cancer Symposium, and a poster presentation.

The company's recent prior events are listed below:

- Nov 19 - 21, 2024 – Jefferies London Healthcare Conference
- Dec 10 - 13, 2024 – San Antonio Breast Cancer Symposium (SABCS) with Flamingo-01 Poster, Booth, & Conference Room
- Dec 19, 2024 – Annual Meeting of Stockholders
- Feb 10 - 11, 2025 – BIO CEO & Investor Conference
- Mar 6 - 7, 2025 – German Breast Group Annual Scientific Meeting
- May 14 - 16, 2025 – ESMO Breast Conference in Germany with Flamingo-01 Poster & Booth
- May 20, 2025 – H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
- Jun 2, 2025 – American Society of Clinical Oncology (ASCO) with Flamingo-01 Poster
- Jun 4, 2025 – Noble Emerging Growth Virtual Conference
- Jun 5, 2025 – Jefferies Global Healthcare Conference
- Jun 16 - 19, 2025 – BIO International Convention (partnering conference)

Greenwich LifeSciences is focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. The company has commenced a Phase III clinical trial, FLAMINGO-01, which is designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients with residual disease or high-risk pathologic complete response at surgery. The trial is led by Baylor College of Medicine and includes US and European clinical sites from university-based hospitals and academic and cooperative networks, with plans to open up to 150 sites globally.

The company's CEO interviews and corporate events highlight its commitment to advancing its pipeline and engaging with stakeholders. For more information on Greenwich LifeSciences and the FLAMINGO-01 trial, please visit the company's website at [1] https://www.greenwichlifesciences.com/ and clinicaltrials.gov at [2] https://clinicaltrials.gov/.

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130703/0/en/Greenwich-LifeSciences-Provides-Update-on-CEO-Interviews-Corporate-Events.html
[2] https://www.stocktitan.net/news/GLSI/greenwich-life-sciences-provides-update-on-ceo-interviews-corporate-83za57qvkw1v.html